Publication: Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease
0
0
Issued Date
2005
Resource Type
File Type
application/pdf
ISSN
1251562
Other identifier(s)
2-s2.0-17744370178
Rights Holder(s)
มหาวิทยาลัยศรีนครินทรวิโรฒ
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol 36, No.1 (2005), p.221-227
Suggested Citation
Srisurapanon S., Louisirirotchanakul S., Sumransurp K., Ratanasrithong M., Chuenchitra T., Jintakatkorn S., Wasi C. Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease. Southeast Asian Journal of Tropical Medicine and Public Health. Vol 36, No.1 (2005), p.221-227. Retrieved from: https://hdl.handle.net/20.500.14740/6319
Abstract
The responsiveness of gp41 antibody against epitope ELDKWA in HIV-1 infected subjects is of importance in neutralizing viral infectivity and for being related to disease progression. In this study, antibody titers to this neutralizing epitope from HIV-1 infected subjects at asymptomatic and AIDS stages in Thailand were investigated by peptide ELISA. The results showed that the frequency of antibody production against this neutralizing epitope was low (15-35%). Moreover, antibody titers to this epitope in sera from AIDS patients were significantly lower than those in sera from asymptomatic subjects which were collected in the same year (p=0.001). Comparison between the past (1992-1994) and present (2002) sera from asymptomatic infected individuals revealed that the earlier panel contained lower antibody titers than the later panel did (p=0.05). In addition, random sera for HIV-1 infected subjects who were infected by diverse genetic subtypes, (A through G) including CRF 01_AE, had low titers of antibody to this region as well. It is assumed that antibody production to this epitope is low and related to the stage of HIV-1 infection.
Subject(s)
Epitope
Glutamylleucylaspartyllysyltryptophylalanine
Glycoprotein gp 41 antibody
Neutralizing antibody
Protein antibody
Unclassified drug
Amino acid sequence
Antibody production
Antibody titer
Antigen binding
Article
Blood analysis
Blood sampling
Controlled study
Disease association
Disease classification
Disease course
Disease severity
Enzyme linked immunosorbent assay
Frequency analysis
Genetic variability
Human
Human immunodeficiency virus 1
Human immunodeficiency virus infection
Major clinical study
Peptide analysis
Randomization
Statistical significance
Symptomatology
Thailand
Viral genetics
Virus infectivity
Virus typing
Glutamylleucylaspartyllysyltryptophylalanine
Glycoprotein gp 41 antibody
Neutralizing antibody
Protein antibody
Unclassified drug
Amino acid sequence
Antibody production
Antibody titer
Antigen binding
Article
Blood analysis
Blood sampling
Controlled study
Disease association
Disease classification
Disease course
Disease severity
Enzyme linked immunosorbent assay
Frequency analysis
Genetic variability
Human
Human immunodeficiency virus 1
Human immunodeficiency virus infection
Major clinical study
Peptide analysis
Randomization
Statistical significance
Symptomatology
Thailand
Viral genetics
Virus infectivity
Virus typing
